EPISODE 65: What Doctors, Telehealth Companies & Consumers Need to Know About The Legal Side of Peptides with Dustin Robinson

<p>Welcome back to <em>Peptides for Women</em> podcast!</p><p>In this episode, I’m joined by <strong>Dustin Robinson</strong>, founding partner of LumaLex Law, an attorney, CPA, and entrepreneur who works with companies in emerging and highly regulated industries. We’re talking about the legal and regulatory side of the peptide industry, including research-use peptides, compounding pharmacies, telehealth, social media, and what doctors and consumers should understand as the industry continues to evolve.</p><p>Dustin shares why peptides, psychedelics, cannabis, healthcare, and other industries can be so complicated from a legal perspective. We also talk about the differences between research-use-only (RUO) products and regulated compounding pharmacies, how state and federal regulations can overlap, and why the laws surrounding peptides can change so quickly.</p><p>We also get into the recent discussions around peptides being considered for the 503A bulk drug list, what that could mean for access, the future of peptide supply chains, and why the demand for peptides could create new challenges for pharmacies and API manufacturers.</p><p>Finally, Dustin explains some of the legal risks around affiliate marketing and social media, including why peptide companies and influencers need to be careful about what they say online and how Meta handles content related to regulated industries.</p><p><strong>In this episode, we cover:</strong></p><ul><li><p>Why emerging industries like peptides, psychedelics, cannabis, and healthcare have complicated legal frameworks</p></li><li><p>How Dustin’s firm uses AI and legal technology to keep up with changing regulations</p></li><li><p>Corporate practice of medicine (CPOM) and why telehealth companies need to understand state-specific laws</p></li><li><p>How MSO-PC structures work and why they can be different from state to state</p></li><li><p>The difference between 503A compounding pharmacies and RUO products</p></li><li><p>Why an RUO product is not the same thing as a prescription</p></li><li><p>The legal risks doctors may face when using RUO products with patients</p></li><li><p>Why some peptides have been difficult to compound through 503A pharmacies</p></li><li><p>The recent PCAC discussions around several peptides and what could happen next</p></li><li><p>FDA rulemaking and the idea of “enforcement discretion”</p></li><li><p>Why peptide demand could potentially outpace the regulated supply chain</p></li><li><p>Where pepti